Tuesday, 10 March 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 10 March 2026
News

Obesity rival plays the long game

Posted 10 March 2026 AM

Roche partner Zealand Pharma has reported Phase 2 results for its much-hyped amylin analog which it described as positive, but which the market saw as disappointing, punishing the pharma by shaving a third off the share price.

The results showed petrelintide achieved up to 10.7 per cent mean body weight reduction at week 42 versus 1.7 per cent with placebo. Analysts were aiming for at least 12 per cent based on Lilly's pipeline asset eloralintide, which saw much higher weight loss in its phase 2 trial, and were reluctant to overlook the large difference.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.